Phase II trial of TapImmune's TPIV-100 vaccine in patients with HER2/neu-positive breast cancer
Phase of Trial: Phase I/II
Latest Information Update: 07 Jun 2016
At a glance
- Drugs TPIV 100 (Primary)
- Indications Breast cancer
- Focus Therapeutic Use
- 07 Jun 2016 According to a TapImmune media release, the company plans to initiate this trial in 2017.
- 07 Dec 2015 According to a TapImmune Inc. media release, data will be presented at the 2015 San Antonio Breast Cancer Symposium.
- 21 May 2015 Planned initiation date changed from 1 Dec 2014 to 1 Sep 2015.